{'fraction_non_alphanumeric': 0.04536082474226804, 'fraction_numerical': 0.016494845360824743, 'mean_word_length': 5.942857142857143, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
GLP‐1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c‐JNK

Liraglutide, a Glucagon‐like peptide‐1(GLP‐1) analogue with 97% sequence identity to human GLP‐1, increases insulin secretion and insulin sensitivity. Its effect on non‐alcoholic fatty liver disease (NAFLD) remains poorly understood. In this study, we examined whether liraglutide can protect against inflammatory stress by inhibiting activation of c‐Jun N‐terminal protein kinase (JNK).